Sign in or create an account to add this stock to your watchlist.
About Globus Medical (NYSE:GMED)
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:GMED
CUSIP37957720
Phone610-930-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio7.45
Quick Ratio6.15
Price-To-Earnings
Trailing P/E Ratio40.13
Forward P/E Ratio34.76
P/E Growth2.81
Sales & Book Value
Annual Sales$635.98 million
Price / Sales8.10
Cash Flow$1.8108 per share
Price / Cash29.18
Book Value$10.54 per share
Price / Book5.01
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$107.34 million
Net Margins18.05%
Return on Equity14.51%
Return on Assets13.13%
Miscellaneous
Employees1,500
Outstanding Shares97,470,000
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) announced its quarterly earnings results on Wednesday, May, 2nd. The medical device company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.36 by $0.05. The medical device company had revenue of $174.41 million for the quarter, compared to analyst estimates of $167.95 million. Globus Medical had a net margin of 18.05% and a return on equity of 14.51%. Globus Medical's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 earnings per share. View Globus Medical's Earnings History.
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $1.52 from $1.50 for the period, compared to the Thomson Reuters consensus estimate of $1.50. The company issued revenue guidance of $695 million from $690 million, compared to the consensus revenue estimate of $690.92 million.
What price target have analysts set for GMED?
11 brokers have issued 1-year price targets for Globus Medical's stock. Their forecasts range from $36.00 to $60.00. On average, they expect Globus Medical's share price to reach $50.6250 in the next twelve months. View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (5/4/2018)
- 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation." (3/12/2018)
- 3. Needham & Company LLC analysts commented, "GMED’s 4Q17 revenue was consistent with its 1/9/18 preannouncement and its EPS beat consensus. Management reiterated 2018 revenue guidance of $690M and adjusted EPS guidance of $1.50. We estimate that the Emerging Technology segment drove much of the upside given the incremental revenue and negligible EPS drag. Gross margin was up 250 bps Y/Y and operating margin was up 60 bps Y/Y. We maintain our Hold rating since we believe that GMED’s valuation appropriately reflects its Emerging Technologies business’ potential." (2/22/2018)
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)
- Mr. David M. Demski, CEO, Group Pres of Emerging Technologies & Director (Age 60)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)
- Mr. David D. Davidar, Co-Founder & Director (Age 52)
- Mr. Daniel T. Scavilla, CFO & Sr. VP (Age 53)
Has Globus Medical been receiving favorable news coverage?
News articles about GMED stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Globus Medical earned a daily sentiment score of 0.21 on Accern's scale. They also assigned news coverage about the medical device company an impact score of 44.52 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.28%), Dimensional Fund Advisors LP (1.79%), Van Berkom & Associates Inc. (1.43%), Royal Bank of Canada (1.31%), GW&K Investment Management LLC (1.25%) and Northern Trust Corp (1.20%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which major investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Nuveen Asset Management LLC, Van Berkom & Associates Inc., Fort Washington Investment Advisors Inc. OH, Segall Bryant & Hamill LLC, Anchor Capital Advisors LLC, GW&K Investment Management LLC and Wells Fargo & Company MN. Company insiders that have sold Globus Medical company stock in the last year include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which major investors are buying Globus Medical stock?
GMED stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Cookson Peirce & Co. Inc., Federated Investors Inc. PA, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Prudential Financial Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $52.84.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $5.10 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
Globus Medical (NYSE:GMED) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Globus Medical in the last 12 months. Their average twelve-month price target is $50.6250, suggesting that the stock has a possible downside of 4.19%. The high price target for GMED is $60.00 and the low price target for GMED is $36.00. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.55 | 2.55 | 2.58 | 2.45 |
| Ratings Breakdown: | 1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $50.6250 | $49.50 | $46.2857 | $35.00 |
| Price Target Upside: | 4.19% downside | 2.29% downside | 6.44% downside | 4.35% downside |
Globus Medical (NYSE:GMED) Consensus Price Target History
Globus Medical (NYSE:GMED) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Globus Medical (NYSE:GMED) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Globus Medical (NYSE GMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.44%
Institutional Ownership Percentage: 62.82%
Globus Medical (NYSE GMED) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/30/2018 | David C Paul | Insider | Sell | 827,004 | $51.81 | $42,847,077.24 | 1,096,461 |  |
| 4/26/2018 | David C Paul | Chairman | Sell | 725,000 | $51.81 | $37,562,250.00 | 1,096,461 | |
| 4/19/2018 | David M Demski | CEO | Sell | 149,109 | $51.00 | $7,604,559.00 | 192,018 | |
| 4/13/2018 | David M Demski | CEO | Sell | 50,891 | $51.00 | $2,595,441.00 | 152,701 | |
| 4/10/2018 | Daniel T Scavilla | VP | Sell | 100,000 | $50.00 | $5,000,000.00 | 18,210 | |
| 3/28/2018 | Eric Schwartz | VP | Sell | 24,000 | $50.00 | $1,200,000.00 | 24,000 | |
| 12/15/2017 | Steven Payne | CAO | Sell | 3,076 | $39.30 | $120,886.80 | 23,847 | |
| 12/13/2017 | Anthony L Williams | President | Sell | 15,000 | $38.30 | $574,500.00 | 15,000 | |
| 12/4/2017 | David D Davidar | Director | Sell | 55,383 | $40.66 | $2,251,872.78 | 752,236 | |
| 11/9/2017 | A Brett Murphy | Insider | Sell | 51,449 | $35.00 | $1,800,715.00 | 49,768 | |
| 9/6/2017 | A Brett Murphy | Insider | Sell | 15,000 | $29.99 | $449,850.00 | 101,217 | |
| 6/5/2017 | Anthony L Williams | President | Sell | 16,153 | $31.94 | $515,926.82 | 16,153 | |
| 8/5/2016 | A Brett Murphy | Insider | Sell | 107,692 | $23.37 | $2,516,762.04 | 190,917 | |
| 1/6/2016 | Robert Liptak | Director | Sell | 15,300 | $27.50 | $420,750.00 | 26,159 | |
| 1/4/2016 | Kurt Wheeler | Director | Sell | 255 | $27.50 | $7,012.50 | 44,319 | |
| 5/28/2015 | Steven Payne | CAO | Sell | 3,076 | $25.92 | $79,729.92 | | |
| 3/19/2015 | David C Paul | CEO | Sell | 1,922,000 | $25.00 | $48,050,000.00 | | |
| 1/15/2014 | David Demski | COO | Sell | 96,813 | $20.51 | $1,985,634.63 | 381,365 | |
| 12/31/2013 | David Demski | COO | Sell | 3,187 | $20.25 | $64,536.75 | 478,178 | |
| 12/20/2013 | David Demski | COO | Sell | 50,000 | $19.75 | $987,500.00 | 481,365 | |
| 12/6/2013 | Robert Liptak | Director | Sell | 25,000 | $19.36 | $484,000.00 | 26,159 | |
| 12/3/2013 | David Davidar | VP | Sell | 75,000 | $19.25 | $1,443,750.00 | 897,275 | |
| 11/27/2013 | David Demski | COO | Sell | 37,323 | $19.25 | $718,467.75 | 531,365 | |
| 11/1/2013 | David M Demski | COO | Sell | 112,677 | $18.59 | $2,094,665.43 | | |
| 8/23/2013 | David Davidar | VP | Sell | 7,278 | $18.20 | $132,459.60 | 997,499 | |
| 8/22/2013 | David Demski | COO | Sell | 44,154 | $17.95 | $792,564.30 | 681,365 | |
| 7/5/2013 | David D Davidar | VP | Sell | 10,000 | $17.15 | $171,500.00 | | |
| 7/1/2013 | David D Davidar | VP | Sell | 20,000 | $16.56 | $331,200.00 | | |
| 6/26/2013 | David D Davidar | VP | Sell | 150,000 | $16.71 | $2,506,500.00 | | |
| 8/8/2012 | David C Paul | CEO | Sell | 3,039,385 | $11.16 | $33,919,536.60 | | |
| 8/8/2012 | David D Davidar | VP | Sell | 166,885 | $11.16 | $1,862,436.60 | | |
| 8/8/2012 | David M Demski | COO | Sell | 98,957 | $11.16 | $1,104,360.12 | | |
| 8/8/2012 | Kurt Wheeler | Director | Sell | 804,232 | $11.16 | $8,975,229.12 | | |
| 8/8/2012 | Steven Payne | CAO | Sell | 2,305 | $11.16 | $25,723.80 | | |
(Data available from 1/1/2013 forward)
Globus Medical (NYSE GMED) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Globus Medical Announces Appointment of Orthopedic Trauma Division’s Vice President of Sales
finance.yahoo.com - May 21 at 4:29 PM |
 | $167.71 Million in Sales Expected for Globus Medical Inc (GMED) This Quarter
www.americanbankingnews.com - May 18 at 3:50 AM |
| $0.35 Earnings Per Share Expected for Globus Medical Inc (GMED) This Quarter
www.americanbankingnews.com - May 16 at 1:05 PM |
| Globus Medical Announces Positive Clinical Results for Lateral Expandable Technology
finance.yahoo.com - May 15 at 4:51 PM |
| Globus Medical Announces Corporate Alliance Partnership with the Society of Lateral Access Surgery
finance.yahoo.com - May 10 at 4:40 PM |
| Brokers Issue Forecasts for Globus Medical Inc's Q3 2018 Earnings (GMED)
www.americanbankingnews.com - May 7 at 3:23 AM |
| William Blair Comments on Globus Medical Inc's Q2 2018 Earnings (GMED)
www.americanbankingnews.com - May 7 at 2:11 AM |
| Q2 2018 Earnings Forecast for Globus Medical Inc Issued By Oppenheimer (GMED)
www.americanbankingnews.com - May 7 at 2:11 AM |
| Zacks Investment Research Downgrades Globus Medical (GMED) to Hold
www.americanbankingnews.com - May 5 at 12:57 PM |
| Globus Medical Inc to Post Q2 2018 Earnings of $0.34 Per Share, Piper Jaffray Forecasts (GMED)
www.americanbankingnews.com - May 4 at 7:57 AM |
| Oppenheimer Analysts Give Globus Medical (GMED) a $52.00 Price Target
www.americanbankingnews.com - May 3 at 11:43 PM |
| Morgan Stanley Boosts Globus Medical (GMED) Price Target to $58.00
www.americanbankingnews.com - May 3 at 11:03 PM |
| Globus Medical (GMED) Price Target Raised to $58.00 at Needham & Company LLC
www.americanbankingnews.com - May 3 at 2:15 PM |
 | BRIEF-Globus Medical Reports Q1 Non-GAAP Earnings Per Share $0.41
www.reuters.com - May 3 at 9:17 AM |
 | Globus Medical (GMED) Tops Q1 EPS by 5c; Raises Outlook
www.streetinsider.com - May 3 at 9:17 AM |
 | Globus Medical (GMED) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:17 AM |
 | Globus Medical Inc. Boosts 2018 Outlook After a Strong First Quarter
www.fool.com - May 3 at 7:18 AM |
| Globus Medical (GMED) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - May 2 at 9:19 PM |
| Globus Medical (GMED) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 6:08 PM |
| Globus Medical Reports First Quarter 2018 Results
finance.yahoo.com - May 2 at 4:34 PM |
| David C. Paul Sells 827,004 Shares of Globus Medical Inc (GMED) Stock
www.americanbankingnews.com - April 30 at 10:12 PM |
| David C. Paul Sells 725,000 Shares of Globus Medical Inc (GMED) Stock
www.americanbankingnews.com - April 30 at 10:10 PM |
| Globus Medical: Innovating Beyond The Spine Market
seekingalpha.com - April 30 at 9:35 AM |
| Globus Medical Inc (GMED) Expected to Announce Quarterly Sales of $167.68 Million
www.americanbankingnews.com - April 30 at 1:50 AM |
| Globus Medical Inc (GMED) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 3:24 AM |
| Globus Medical Inc (GMED) Expected to Post Earnings of $0.36 Per Share
www.americanbankingnews.com - April 28 at 11:12 PM |
| Globus Medical (GMED) Upgraded at ValuEngine
www.americanbankingnews.com - April 26 at 2:04 PM |
| Critical Analysis: Globus Medical (GMED) & Invuity (IVTY)
www.americanbankingnews.com - April 25 at 1:38 PM |
| Globus Medical (GMED) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 25 at 12:47 PM |
| Globus Medical (GMED) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 6:52 AM |
| Globus Medical Inc (GMED) CEO Sells $7,604,559.00 in Stock
www.americanbankingnews.com - April 20 at 7:22 PM |
| Globus Medical (GMED) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM |
| Globus Medical (GMED) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 19 at 1:22 PM |
| Globus Medical (GMED) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM |
| BTIG Sees Limited Upside For Globus Medical, Downgrades To Neutral
finance.yahoo.com - April 17 at 9:46 AM |
| Globus Medical Inc (GMED) CEO David M. Demski Sells 50,891 Shares
www.americanbankingnews.com - April 16 at 7:14 PM |
| Globus Medical's (GMED) "Neutral" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - April 16 at 8:45 AM |
| Zacks: Analysts Anticipate Globus Medical Inc (GMED) Will Post Quarterly Sales of $167.68 Million
www.americanbankingnews.com - April 14 at 5:43 AM |
| Globus Medical (GMED) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM |
| Oppenheimer Analysts Give Globus Medical (GMED) a $35.00 Price Target
www.americanbankingnews.com - April 13 at 8:19 PM |
| Globus Medical (GMED) Receives Underweight Rating from Barclays
www.americanbankingnews.com - April 12 at 3:27 PM |
| $0.36 Earnings Per Share Expected for Globus Medical Inc (GMED) This Quarter
www.americanbankingnews.com - April 12 at 1:15 AM |
| Globus Medical Inc (GMED) VP Sells $5,000,000.00 in Stock
www.americanbankingnews.com - April 11 at 7:11 PM |
| Globus Medical launches two new spinal implants
seekingalpha.com - April 6 at 4:43 PM |
 | Globus Medical Announces Launch of ELSA® Expandable Lateral Spacer System
globenewswire.com - April 5 at 4:29 PM |
| Globus Medical Announces Launch of ELSA® Expandable Lateral Spacer System
finance.yahoo.com - April 5 at 4:29 PM |
| Globus Medical (GMED) Upgraded to Buy by Needham & Company LLC
www.americanbankingnews.com - April 4 at 12:49 PM |
| BTIG Research Reiterates Buy Rating for Globus Medical (GMED)
www.americanbankingnews.com - March 31 at 8:16 PM |
| Barclays Boosts Globus Medical (GMED) Price Target to $29.00
www.americanbankingnews.com - March 31 at 5:28 PM |
| Globus Medical (GMED) Upgraded by Morgan Stanley to Overweight
www.americanbankingnews.com - March 31 at 12:49 PM |
Globus Medical (NYSE:GMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Globus Medical (NYSE:GMED) Income Statement, Balance Sheet and Cash Flow Statement
Globus Medical (NYSE GMED) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
